Newer treatments for decompensated heart failure: focus on levosimendan
Ferenc FollathUniversity Hospital Zürich, Steering Group Drug Therapy, Zürich, SwitzerlandAbstract: Acute heart failure (AHF) is a major cause of hospitalizations. Severe dyspnea, pulmonary congestion and low cardiac output with peripheral vasoconstriction and renal hypoperfusion i...
Saved in:
Main Author: | Ferenc Follath (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
by: M. V. Lediakhova, et al.
Published: (2018) -
Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap
by: Conti N, et al.
Published: (2021) -
The Use of Levosimendan for the Treatment of Heart Failure and its Potential Organoprotective Effects
by: N. B. Lebedeva, et al.
Published: (2022) -
CARDIORENAL INTERACTION IN DECOMPENSATED CHRONIC HEART FAILURE
by: Zh. D. Kobalava, et al.
Published: (2016) -
FACTORS EFFECTING THE DECOMPENSATION OF CHRONIC HEART FAILURE IN THE ELDERLY
by: V. N. Larina, et al.
Published: (2015)